PDI inks one-year sales agreement

Share this article:
Contract sales firm PDI has inked a one-year sales agreement for a cardiology drug with an unnamed “top-10 pharmaceutical company.”

The initiative, expected to bring in $13 million in revenue, will target primary care physicians and cardiologists and was scheduled to begin April 2.

The announcement is viewed as a much-needed boost for PDI, which announced a decision by a “large pharma company” client not to renew a $35 million contract sales engagement with the firm. PDI previously expected that one-year deal to be extended through the end of 2007.

PDI has endured four major contract losses during the past year.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.